Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. The current PI3K 3C inhibitors in use in ...

ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. There are several clinical trials that are ...

Monday, Relay Therapeutics Inc. RLAY shared interim data for RLY-2608 from the ReDiscover study of RLY-2608 alone, in combination with fulvestrant, and in combination with fulvestrant and ribociclib ...

The EMERALD trial investigators randomly assigned 478 patients with ER+, HER2- advanced breast cancer on a 1:1 basis to receive elacestrant or physician’s choice of standard therapy, which was defined ...

First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent targeted therapy payloads while mitigating ...

Faeth Therapeutics, a clinical-stage biotechnology company advancing therapies that systematically target tumor metabolism, ...

The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and fulvestrant to treat locally advanced, PIK3CA ...

Actinic keratosis affects more than 10% of Europeans and is considered the most common pre-cancerous dermatological condition driven by an overactive PI3K/mTOR pathway. Bimiralisib gel is a selective ...